NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
NeurAxis (NYSE American: NRXS), a medical technology company specializing in neuromodulation therapies for chronic conditions in children and adults, is set to participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The event will be held virtually, featuring a webcasted presentation at 12:30 p.m. ET and one-on-one meetings with investors.
Investors can access the webcast through the conference homepage or a direct link, with replay available after the event. To schedule meetings with NeurAxis management, interested parties can contact Lytham Partners or register for the event online. This conference provides an opportunity for NeurAxis to showcase its innovative medical technologies and engage with potential investors.
NeurAxis (NYSE American: NRXS), un'azienda di tecnologia medica specializzata in terapie neuromodulatorie per condizioni croniche in bambini e adulti, parteciperà alla Conferenza degli Investitori Lytham Partners Autunno 2024 il 1 ottobre 2024. L'evento si svolgerà virtualmente, con una presentazione in diretta streaming alle 12:30 p.m. ET e incontri individuali con gli investitori.
Gli investitori possono accedere alla trasmissione in streaming tramite la homepage della conferenza o un link diretto, con la possibilità di rivedere l'evento dopo la sua conclusione. Per pianificare incontri con il management di NeurAxis, le parti interessate possono contattare Lytham Partners o registrarsi per l'evento online. Questa conferenza offre a NeurAxis l'opportunità di mettere in mostra le sue tecnologie mediche innovative e di interagire con potenziali investitori.
NeurAxis (NYSE American: NRXS), una empresa de tecnología médica especializada en terapias de neuromodulación para condiciones crónicas en niños y adultos, participará en la Conferencia de Inversores de Otoño 2024 de Lytham Partners el 1 de octubre de 2024. El evento se llevará a cabo de forma virtual, con una presentación transmitida en vivo a las 12:30 p.m. ET y reuniones uno a uno con los inversores.
Los inversores pueden acceder a la transmisión a través de la página de inicio de la conferencia o un enlace directo, con la opción de ver repetición después del evento. Para programar reuniones con la dirección de NeurAxis, las partes interesadas pueden contactar a Lytham Partners o registrarse para el evento en línea. Esta conferencia ofrece a NeurAxis la oportunidad de mostrar sus tecnologías médicas innovadoras y relacionarse con posibles inversores.
NeurAxis (NYSE American: NRXS), 아동 및 성인의 만성 질환을 위한 신경 조절 요법을 전문으로 하는 의료 기술 회사가 2024년 가을 Lytham Partners 투자자 회의에 2024년 10월 1일 참석할 예정입니다. 이 행사에서는 오후 12시 30분 ET에 진행되는 웹캐스트 발표와 함께 투자자와의 일대일 미팅이 진행됩니다.
투자자들은 회의 홈페이지나 직접 링크를 통해 웹캐스트에 접속할 수 있으며, 행사 종료 후 다시 볼 수 있는 기능도 제공됩니다. NeurAxis 경영진과의 미팅을 예약하려는 경우, 관심 있는 당사자들은 Lytham Partners에 연락하거나 행사에 온라인으로 등록할 수 있습니다. 이 회의는 NeurAxis가 혁신적인 의료 기술을 홍보하고 잠재 투자자와 소통할 수 있는 기회를 제공합니다.
NeurAxis (NYSE American: NRXS), une entreprise de technologie médicale spécialisée dans les thérapies de neuromodulation pour des conditions chroniques chez les enfants et les adultes, participera à la Conférence des Investisseurs d’Automne 2024 de Lytham Partners le 1er octobre 2024. L'événement se déroulera virtuellement, avec une présentation diffusée en direct à 12h30 ET et des réunions individuelles avec les investisseurs.
Les investisseurs peuvent accéder au webcast via la page d'accueil de la conférence ou un lien direct, avec une rediffusion disponible après l'événement. Pour planifier des réunions avec la direction de NeurAxis, les parties intéressées peuvent contacter Lytham Partners ou s'inscrire en ligne pour l'événement. Cette conférence offre à NeurAxis l'opportunité de présenter ses technologies médicales innovantes et d'interagir avec des investisseurs potentiels.
NeurAxis (NYSE American: NRXS), ein Medizinunternehmen, das auf Neuromodulationstherapien für chronische Erkrankungen bei Kindern und Erwachsenen spezialisiert ist, wird an der Lytham Partners Herbst 2024 Investorenkonferenz am 1. Oktober 2024 teilnehmen. Die Veranstaltung findet virtuell statt, mit einer über das Web übertragenen Präsentation um 12:30 Uhr ET sowie Einzelgesprächen mit Investoren.
Investoren können über die Homepage der Konferenz oder einen direkten Link auf die Webcast-Präsentation zugreifen, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist. Um Meetings mit dem Management von NeurAxis zu planen, können interessierte Parteien Lytham Partners kontaktieren oder sich online für die Veranstaltung registrieren. Diese Konferenz bietet NeurAxis die Möglichkeit, seine innovativen Medizintechnologien zu präsentieren und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
Company Webcast
The webcasted presentation will take place at 12:30 p.m. ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2024 or directly at https://app.webinar.net/jvobBr8X2qa. The webcast will also be available for replay following the event.
1×1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Contacts
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
FAQ
When is NeurAxis (NRXS) participating in the Lytham Partners Fall 2024 Investor Conference?
What time is NeurAxis (NRXS) presenting at the Lytham Partners conference?
How can investors access NeurAxis's (NRXS) presentation at the Lytham Partners conference?
Will NeurAxis (NRXS) be available for one-on-one meetings during the Lytham Partners conference?
How can investors arrange a meeting with NeurAxis (NRXS) management during the conference?
